Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C22H16F4N4O3S |
| Molecular Weight | 492.446 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CNC(=O)C1=C(F)C=C(C=C1)N2C(=S)N(C(=O)[C@]23CCOC3)C4=CC=C(C#N)C(=C4)C(F)(F)F
InChI
InChIKey=QKKPJFTYJCXESR-OAQYLSRUSA-N
InChI=1S/C22H16F4N4O3S/c1-28-18(31)15-5-4-14(9-17(15)23)30-20(34)29(19(32)21(30)6-7-33-11-21)13-3-2-12(10-27)16(8-13)22(24,25)26/h2-5,8-9H,6-7,11H2,1H3,(H,28,31)/t21-/m1/s1
| Molecular Formula | C22H16F4N4O3S |
| Molecular Weight | 492.446 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 11:55:28 GMT 2023
by
admin
on
Sat Dec 16 11:55:28 GMT 2023
|
| Record UNII |
JFG7JWH6YL
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Code | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Code | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
77461273
Created by
admin on Sat Dec 16 11:55:28 GMT 2023 , Edited by admin on Sat Dec 16 11:55:28 GMT 2023
|
PRIMARY | |||
|
1351185-54-0
Created by
admin on Sat Dec 16 11:55:28 GMT 2023 , Edited by admin on Sat Dec 16 11:55:28 GMT 2023
|
PRIMARY | |||
|
ONC1-13B
Created by
admin on Sat Dec 16 11:55:28 GMT 2023 , Edited by admin on Sat Dec 16 11:55:28 GMT 2023
|
PRIMARY | MedKoo CAT NO.: 206711, CAS NO.: 1351185-54-0Description: ONC1-13B is an antagonist of androgen receptor, with similar to MDV3100 and ARN-509 mechanism of action. ONC1-13B efficiently inhibits DHT-stimulated PSA expression and proliferation of prostate cancer cells, prevents binding of androgens to the AR ligand-binding domain, androgen-stimulated AR nuclear translocation and co-activator complex formation. In the LnCaP-Z2 xenograft model of prostate cancer ONC1-13B inhibits tumor growth and suppresses PSA expression. Thus ONC1-13B is a new promising anti-androgen demonstrating high efficacy in a preclinical model of prostate cancer, with lower potential for seizures and drug-drug interaction. (last updated: 4/16/2016)Synonym: ONC1-13B, ONC113B, ONC 113B, ONC1-0013B, ONC 10013B, ONC-10013B.IUPAC/Chemical Name: (R)-4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-4-oxo-2-thioxo-7-oxa-1,3-diazaspiro(4.4)nonan-1-yl)-2-fluoro-N-methylbenzamide | ||
|
C148485
Created by
admin on Sat Dec 16 11:55:28 GMT 2023 , Edited by admin on Sat Dec 16 11:55:28 GMT 2023
|
PRIMARY | |||
|
JFG7JWH6YL
Created by
admin on Sat Dec 16 11:55:28 GMT 2023 , Edited by admin on Sat Dec 16 11:55:28 GMT 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |
We describe here the preclinical development of ONC1-13B, antagonist of androgen receptor, with similar to MDV3100 and ARN-509 mechanism of action. It efficiently inhibits DHT-stimulated PSA expression and proliferation of prostate cancer cells, prevents binding of androgens to the AR ligand-binding domain, androgen-stimulated AR nuclear translocation and coactivator complex formation. In the LnCaP-Z2 xenograft model of prostate cancer ONC1-13B inhibits tumor growth and suppresses PSA expression. The in vivo activity of ONC1-13B is comparable to that of MDV3100 at similar doses, and even higher, calculated per unit of concentration in plasma. Distribution of ONC1-13B to the brain is less than that shown for MDV3100 and ARN-509, decreasing the risk of GABA-related seizure development. Additionally ONC1-13B induces significantly lower in vitro CYP3A activity than for example MDV3100 (known strong CYP3A inducer) or ARN-509 and could be well suited for co-therapy with drugs that are known CYP3A substrates. Thus ONC1-13B is a new promising antiandrogen demonstrating high efficacy in a preclinical model of prostate cancer, with lower potential for seizures and drug-drug interaction.
|
||
|
ACTIVE MOIETY |
Originator: AllaChem; Class: Anti-androgen, Anti-neoplastic, Small molecule, Urea compound; Mechanism of Action: Androgen receptor antagonist; Orphan Drug Status: No; On Fast track: No; New Molecular Entity: Yes; Highest Development Phases: Phase I/II for Prostate cancer, Preclinical for Breast cancer; Most Recent Events: 19 Feb 2016 Phase-I/II development is ongoing in Russia, 01 Nov 2013 Phase-I/II clinical trials in Prostate cancer (hormone-refractory metastatic disease) in Russia (PO), 01 Jan 2013 Preclinical trials in Breast cancer in Russia (PO)
|
||
|
ACTIVE MOIETY |
Phase of Trial: Phase I/II; Drug: ONC1 13B(Primary); Indication: Prostate cancer; Focus: Therapeutic Use; Sponsor: AllaChem; Most Recent Event: 08 Nov 2013 New trial record
|
